

Monterrey, Mexico. February 12, 2018 – Alpek, S.A.B. de C.V. (BMV: ALPEK)

Alpek reports 4Q17 EBITDA of U.S. \$141 million

Selected Financial Information

(U.S. \$ Millions)

	4Q17	3Q17	4Q16	(%) 4Q17 vs.		YTD17	YTD16	Ch.%
				3Q17	4Q16			
Total Volume (ktons)	975	1,012	970	(4)	1	4,012	3,938	2
Polyester	752	788	749	(5)	-	3,105	3,004	3
Plastics & Chemicals	224	225	221	-	1	906	934	(3)
Consolidated Revenues	1,321	1,312	1,183	1	12	5,231	4,838	8
Polyester	933	945	851	(1)	10	3,724	3,444	8
Plastics & Chemicals	388	367	332	6	17	1,506	1,394	8
Consolidated EBITDA	141	3	133	4,241	6	384	669	(43)
Polyester	77	(51)	82	253	(6)	147	349	(58)
Plastics & Chemicals	64	54	52	18	21	237	322	(26)
Profit Attributable to Controlling Interest	(30)	(400)	28	92	(209)	(319)	198	(261)
CAPEX and Acquisitions	30	64	75	(54)	(60)	236	345	(32)
Net Debt	1,262	1,192	1,042	6	21			
Net Debt/LTM EBITDA ⁽¹⁾	3.3	3.2	1.6					
Interest Coverage ⁽¹⁾	4.8	5.4	10.5					

(1) Times: Last 12 months

Operating & Financial Highlights (4Q17)

Alpek	<ul style="list-style-type: none"> 4Q17 Consolidated EBITDA of U.S. \$141 million, including a U.S. \$16 million non-cash inventory gain; rapid recovery after 3Q17 Cogeneration power plants' sale process advanced with ContourGlobal 3.3 times Net Debt/EBITDA; 2.5 times excluding M&G A/R provision (U.S. -\$113 million)
Polyester	<ul style="list-style-type: none"> M&G Mexico resumed PET production in 4Q17; Alpek supplies PTA via tolling agreement and secured credit facility The Court of the Administrative Council for Economic Defense in Brazil (CADE) approved the acquisition of PetroquímicaSuape and Citepe PET antidumping cases moving forward in the United States and Canada
Plastics & Chemicals (P&C)	<ul style="list-style-type: none"> 4Q17 P&C EBITDA of U.S. \$64 million, including a U.S. \$5 million non-cash inventory gain Margin expansion in polypropylene (PP) and caprolactam (CPL) more than offset flat 4Q17 volume

This release contains forward-looking information based on numerous variables and assumptions that are inherently uncertain. They involve judgments with respect to, among other things, future economic, competitive and financial market conditions and future business decisions, all of which are difficult or impossible to predict accurately. Accordingly, results could vary from those set forth in this release. The report presents unaudited financial information based on International Financial Reporting Standards (IFRS). Figures are stated in nominal Mexican pesos (\$) and in current U.S. Dollars (U.S. \$), as indicated. Where applicable, peso amounts were translated into U.S. Dollars using the average exchange rate of the months during which operations were recorded. Financial ratios are calculated in U.S. Dollars. Due to the rounding up of figures, small differences may occur when calculating percent changes from one period to the other.

Message from the CEO

Alpek's Consolidated EBITDA returned to a normalized level in the fourth quarter, supported by solid performance in both business segments. The restart of M&G Polímeros México, S.A. de C.V. (M&G Mexico), robust polypropylene (PP) margins and a rising oil price environment contributed to a rapid recovery after 3Q17.

Consolidated 4Q17 EBITDA was U.S. \$141 million, including a U.S. \$16 million non-cash inventory gain. Higher feedstock prices resulted in an U.S. \$11 million inventory gain in Polyester and a U.S. \$5 million gain in Plastics & Chemicals (P&C). Adjusting for inventory gains and the U.S. -\$113 million M&G A/R provision in 3Q17, Comparable 4Q17 Consolidated EBITDA was up 6% and 15% versus 4Q16 and 3Q17 respectively.

Comparable 4Q17 Polyester EBITDA increased 22% quarter-on-quarter to U.S. \$66 million as M&G Mexico resumed operations and PET margins posted a sequential recovery amid rising oil and feedstock prices. In addition, the P&C segment closed the year with Comparable EBITDA of U.S. \$59 million, its fourth consecutive quarter above Guidance driven by higher than expected PP margins.

In November 2017, M&G Mexico resumed PET production under a temporary tolling agreement with Alpek, who supplies the required feedstocks (e.g. PTA and MEG) and pays a tolling fee in exchange for PET from the Altamira facility. The tolling agreement was recently complemented by a credit agreement through which Alpek will provide up to U.S. \$60 million in secured financing to M&G Mexico subject to certain conditions. The combination of tolling and credit agreement is intended to support M&G Mexico's PET operations while a permanent restructuring plan is presented to Alpek and other creditors. Alpek's priorities in M&G Mexico's restructuring process are: i) maximizing the recovery of its claims and ii) maintaining its PTA supply to the restructured entity.

The restructuring process associated to the integrated PTA-PET plant that was being constructed by M&G in Corpus Christi, TX also advanced during 4Q17. M&G USA Corporation (M&G USA) filed for bankruptcy in Delaware and received approval to begin the sale of certain assets, including the Corpus Christi plant. Bidding procedures are scheduled to occur in 1Q18. Alpek's priority in M&G USA's restructuring process is to reaffirm its Corpus Christi capacity rights under the original agreements or as a bidder for the Corpus Christi assets.

Other key, ongoing events include: i) the formal sale process of our two cogeneration power plants, ii) the evaluation process by the Court of the Administrative Council for Economic Defense (CADE), and iii) the PET antidumping cases in the United States and Canada.

During 4Q17, Alpek selected ContourGlobal and moved forward in the sale process of its cogeneration power plants in Cosoleacaque and Altamira, Mexico.

In Brazil, the CADE Court approved the acquisition of PetroquímicaSuape and Citepe from Petrobras. As part of the approval process, Alpek proposed entering into a merger control agreement (Acordo de Controle de Concentração – ACC), committing to maintain an environment of effective competition.

Regarding the PET antidumping cases, the United States Department of Commerce (USDOC) initiated its investigations and the United States International Trade Commission (USITC) issued a preliminary determination of material injury caused by PET imports from Brazil, Indonesia, Korea, Pakistan and Taiwan. Separately, the Canada Border Services Agency (CBSA) imposed preliminary duties ranging from 22% to 77% on PET imports from China, India, Oman and Pakistan.

On the investment front, Capex was U.S. \$30 million in 4Q17 and totaled U.S. \$236 million in 2017, as planned. Our strategic capex program reached an important milestone this year with the start-up of two projects; the propylene storage spheres and the expandable polystyrene (EPS) capacity expansion in Mexico. Moreover, progress continued in the 350 MW Altamira cogeneration power plant as approximately 80% of the total investment had been disbursed at the close of 2017.

Alpek maintains a solid financial position supported by a strong balance sheet and liquidity. At the close of 4Q17, Net Debt totaled U.S. \$1.262 billion and Net Debt to EBITDA was 3.3 times or 2.5 times when adjusted for the U.S. -\$113 million M&G A/R provision that affected EBITDA in 3Q17. Furthermore, the balance of Cash and Cash Equivalents was U.S. \$484 million as of year-end.

We have an optimistic outlook for 2018 as we anticipate continuous M&G Mexico PET plant operations, PET margin recovery from the 2017 multi-year low and a higher annual average Brent oil price. 2018 Guidance will be disclosed tomorrow, prior to our 4Q17 Conference Call.

Results by Business Segment

Polyester

(Purified Terephthalic Acid (PTA), Polyethylene Terephthalate (PET), Polyester fibers – 71% of Alpek's Net Sales)

Fourth quarter 2017 Polyester revenue was up 10% year-on-year and down 1% quarter-on-quarter amid a higher price environment. Average 4Q17 Polyester prices increased 9% and 3% when compared with 4Q16 and 3Q17, respectively, reflecting the rise in feedstock prices such as paraxylene. For the full-year 2017, revenue was up 8% versus 2016 as average prices increased 5% and volume was 3% higher.

4Q17 Polyester volume was flat when compared to 4Q16 and down 5% versus 3Q17. Lower PTA volume supplied to M&G in Mexico and Brazil were partially offset by incremental PET sales during 4Q17. In contrast, 2017 segment volume was 3% higher than in 2016 as the M&G PTA supply disruption was more than offset by the integration of Selenis Canada Inc. (PET), plus organic PET volume growth in the United States, Mexico and Argentina.

Fourth quarter 2017 segment EBITDA was U.S. \$77 million, including an U.S. \$11 million non-cash inventory gain. Adjusting for inventory gains and the U.S. -\$113 million M&G A/R provision in 3Q17, Comparable 4Q17 Polyester EBITDA was U.S. \$66 million, flat when compared to 4Q16 and up 22% when compared with 3Q17. The M&G Mexico restart, PET margin recovery and a rising feedstock price environment contributed to Comparable Polyester EBITDA growth quarter-on-quarter. For the full-year 2017, Polyester EBITDA was U.S. \$147 million, including the M&G A/R provision, a U.S. \$14 million non-cash inventory gain and a U.S. \$12 million one-time gain from the Selenis Canada Inc. acquisition (2016). Comparable 2017 Polyester EBITDA was U.S. \$234 million, down 29% versus 2016 affected primarily by lower PET margins, the M&G PTA supply disruption and higher secondary feedstock costs (e.g. isophthalic acid or IPA).

Plastics & Chemicals (P&C)

(Polypropylene (PP), Expandable Polystyrene (EPS), Caprolactam (CPL), Other products – 29% of Alpek's Net Sales)

4Q17 P&C revenue increased 17% year-on-year and 6% quarter-on-quarter due to higher average prices. Average fourth quarter 2017 P&C prices were up 15% and 6% when compared with 4Q16 and 3Q17 respectively, driven mainly by the rise in feedstock prices such as propylene and styrene. For the full year 2017, revenue grew 8% versus 2016 as lower volume was more than offset by an 11% increase in average prices.

Fourth quarter 2017 P&C volume was up 1% year-on-year and flat when compared to 3Q17. On an annual basis, 2017 P&C volume was 3% lower than 2016 as unplanned refinery outages in Mexico weighed on propylene supply. Also, lower domestic ethylene oxide and ammonia supply affected Alpek's specialty chemical and caprolactam businesses.

Segment EBITDA was U.S. \$64 million in 4Q17, including a U.S. \$5 million inventory gain. Adjusting for the inventory gain, Comparable 4Q17 P&C EBITDA was U.S. \$59 million, up 12% and 9% when compared with 4Q16 and 3Q17 driven by PP and CPL. For the full-year 2017, P&C EBITDA was U.S. \$237 million, including an U.S. \$8 million non-cash inventory gain. Comparable P&C EBITDA was U.S. \$229 million, 26% lower than 2016 which benefited from record PP and EPS EBITDA. However, P&C EBITDA was consistently above 2017 Guidance.

Consolidated Financial Results

Net Sales: Net Sales for the fourth quarter totaled U.S. \$1.3 billion, up 12% year-on-year and 1% quarter-on-quarter, mainly due to higher average consolidated prices in both business segments. Average 4Q17 consolidated prices increased 11% and 5% when compared with 4Q16 and 3Q17, respectively. 4Q17 consolidated volume was up 1% year-on-year and down 4% quarter-on-quarter. Accumulated net sales as of December 31, 2017 totaled U.S. \$5.2 billion, 8% higher than 2016 driven by increases of 6% and 2% in average prices and volume respectively.

EBITDA: 4Q17 EBITDA was U.S. \$141 million, including a U.S. \$16 million non-cash inventory gain. Adjusting for the inventory gain, Comparable Consolidated EBITDA was U.S. \$124 million, U.S. \$108 million and U.S. \$117 million in 4Q17, 3Q17 and 4Q16 respectively. Accumulated EBITDA as of December 31, 2017 was U.S. \$384 million, including the U.S. -\$113 million M&G A/R provision, a U.S. \$22 million non-cash inventory gain and a U.S. \$12 million one-time gain from the Selenis Canada Inc. acquisition (2016). Comparable Consolidated 2017 EBITDA totaled U.S. \$462 million, down 27% versus 2016 mainly due to the anticipated margin contraction in PP and PET, plus the M&G PTA supply disruption.

Profit (Loss) Attributable to Controlling Interest: Loss Attributable to Controlling Interest for the fourth quarter of 2017 was U.S. -\$30 million due to higher Income tax and Fx loss. As a result of the recent U.S. tax reform, which lowered the corporate tax rate, 4Q17 Income tax includes a U.S. -\$65 million adjustment to the U.S. \$223 million deferred tax benefit related to M&G provisions and impairments. In addition, non-cash Fx loss totaled U.S. \$47 million in 4Q17 due to the depreciation of the Mexican Peso. Accumulated 2017 Loss Attributable to Controlling Interest was U.S. -\$319 million, including a net impact of U.S. -\$481 million from non-recurring charges associated to M&G affecting EBITDA, Operating Income, Financial Cost, Net and Income Tax. Adjusting for the non-recurring M&G items, the 2017 Profit Attributable to Controlling Interest was U.S. \$162 million, compared to U.S. \$198 million in 2016.

Capital Expenditures and Acquisitions (Capex): 4Q17 Capex was U.S. \$30 million, compared to U.S. \$75 million and U.S. \$64 million in 4Q16 and 3Q17 respectively. Year-to-date Capex of U.S. \$236 million, 32% lower than the same period last year as investment ramps down due to the completion of Alpek's strategic project program. The majority of these funds were invested in the 350 MW power cogeneration plant in Altamira, Mexico, which advanced as planned.

Net Debt: Consolidated Net Debt as of December 31, 2017 was U.S. \$1.262 billion, up 21% and 6% year-on-year and quarter-on-quarter, respectively. On an absolute basis, Net Debt increased U.S. \$70 million in 4Q17 as the investment of U.S. \$101 million in M&G secured credit rights acquired from Inbursa was partially offset with cash from operations. As of December 31, 2017, Gross Debt was U.S. \$1.747 billion and the Cash balance totaled U.S. \$484 million. Financial ratios at the close of 4Q17 were: Net Debt to EBITDA of 3.3 times and Interest Coverage of 4.8 times. Adjusting for the U.S. -\$113 million M&G A/R provision, Net Debt to EBITDA was 2.5 times and Interest Coverage was 6.2 times.

Appendix A - Tables

TABLE 1 | VOLUME (KTONS)

	4Q17	3Q17	4Q16	(% 4Q17 vs.)		YTD17	YTD16	Ch.%
				3Q17	4Q16			
Total Volume	975	1,012	970	(4)	1	4,012	3,938	2
Polyester	752	788	749	(5)	-	3,105	3,004	3
Plastics and Chemicals	224	225	221	-	1	906	934	(3)

TABLE 2 | PRICE CHANGES (%)

	(% 4Q17 vs.)		YTD17 vs.
	3Q17	4Q16	YTD16
Polyester			
Avg. Ps. Prices	10	4	6
Avg. U.S. \$ Prices	3	9	5
Plastics and Chemicals			
Avg. Ps. Prices	13	10	13
Avg. U.S. \$ Prices	6	15	11
Total			
Avg. Ps. Prices	11	6	8
Avg. U.S. \$ Prices	5	11	6

TABLE 3 | INCOME STATEMENT (U.S. \$ Millions)

	4Q17	3Q17	4Q16	(% 4Q17 vs.)		YTD17	YTD16	Ch.%
				3Q17	4Q16			
Total Revenues	1,321	1,312	1,183	1	12	5,231	4,838	8
Gross Profit	162	126	142	29	15	544	714	(24)
Operating expenses and others	(52)	(596)	(44)	91	(19)	(732)	(182)	(303)
Operating income	110	(470)	98	123	13	(188)	532	(135)
Financial cost, net	(68)	(130)	(36)	47	(92)	(188)	(133)	(41)
Share of losses of associates	-	-	-	-	-	-	-	-
Income Tax	(62)	206	(29)	(130)	(111)	106	(126)	184
Consolidated net income	(20)	(394)	33	95	(161)	(271)	272	(199)
Controlling Interest	(30)	(400)	28	92	(209)	(319)	198	(261)

TABLE 4 | REVENUES

	4Q17	3Q17	4Q16	(%) 4Q17 vs.		YTD17	YTD16	Ch. %
				3Q17	4Q16			
Total Revenues								
Ps. Millions	25,010	23,374	23,428	7	7	98,998	90,192	10
U.S. \$ Millions	1,321	1,312	1,183	1	12	5,231	4,838	8
Domestic Revenues								
Ps. Millions	8,166	8,060	8,491	1	(4)	34,957	33,625	4
U.S. \$ Millions	431	452	429	(5)	1	1,846	1,806	2
Foreign Revenues								
Ps. Millions	16,844	15,314	14,937	10	13	64,042	56,567	13
U.S. \$ Millions	890	859	754	4	18	3,385	3,032	12
Foreign / Total (%)	67	66	64			65	63	

TABLE 5 | OPERATING INCOME AND EBITDA

	4Q17	3Q17	4Q16	(%) 4Q17 vs.		YTD17	YTD16	Ch. %
				3Q17	4Q16			
Operating Income								
Ps. Millions	2,084	(8,377)	1,944	125	7	(2,854)	9,863	(129)
U.S. \$ Millions	110	(470)	98	123	13	(188)	532	(135)
EBITDA								
Ps. Millions	2,660	59	2,647	4,408	-	7,483	12,425	(40)
U.S. \$ Millions	141	3	133	4,241	6	384	669	(43)

TABLE 6 | COMPARABLE EBITDA

	4Q17	3Q17	4Q16	(%) 4Q17 vs.		YTD17	YTD16	Ch. %
				3Q17	4Q16			
EBITDA								
Ps. Millions	2,660	59	2,647	4,408	-	7,483	12,425	(40)
U.S. \$ Millions	141	3	133	4,241	6	384	669	(43)
Adjustments*								
Ps. Millions	(309)	1,863	(327)	(117)	5	1,322	(622)	312
U.S. \$ Millions	(16)	105	(16)	(116)	(1)	79	(32)	346
Comparable EBITDA								
Ps. Millions	2,350	1,922	2,320	22	1	8,806	11,803	(25)
U.S. \$ Millions	124	108	117	15	6	462	637	(27)

*Adjustments: Inventory and non-operating, one-time (gains) losses

TABLE 7 | FINANCIAL COST, NET (U.S. \$ Millions)

	4Q17	3Q17	4Q16	(%) 4Q17 vs.		YTD17	YTD16	Ch. %
				3Q17	4Q16			
Financial Expenses	(23)	(19)	(17)	(24)	(38)	(78)	(76)	(3)
Financial Income	2	2	4	13	(55)	10	15	(32)
Net Financial Expenses	(21)	(17)	(13)	(25)	(68)	(68)	(61)	(11)
Financial Assets Impairment	-	(95)	-	100	-	(95)	-	(100)
Fx Gains (Losses)	(47)	(18)	(23)	(166)	(105)	(25)	(72)	66
Financial Cost, Net	(68)	(130)	(36)	47	(92)	(188)	(133)	(41)

TABLE 8 | NET INCOME (U.S. \$ Millions)

	4Q17	3Q17	4Q16	(%) 4Q17 vs.		YTD17	YTD16	Ch. %
				3Q17	4Q16			
Consolidated Net Income	(20)	(394)	33	95	(161)	(271)	272	(199)
Non-Controlling Interest	10	6	5	65	94	49	75	(35)
Controlling Interest	(30)	(400)	28	92	(209)	(319)	198	(261)
Earnings per Share (U.S. Dollars)	(0.01)	(0.19)	0.01	92	(209)	(0.15)	0.09	(261)
Avg. Outstanding Shares (Millions)*	2,117	2,117	2,117			2,117	2,117	

* The same number of equivalent shares are considered in the periods presented

TABLE 9 | CASH FLOW (U.S. \$ Millions)

	4Q17	3Q17	4Q16	(%) 4Q17 vs.		YTD17	YTD16	Ch. %
				3Q17	4Q16			
EBITDA	141	3	133	4,241	6	384	669	(43)
Net Working Capital & Others	(37)	29	(84)	(228)	55	83	(183)	145
Capital Expenditures & Acq.	(30)	(64)	(75)	54	60	(236)	(345)	32
Financial Expenses	(22)	(17)	(16)	(27)	(35)	(72)	(58)	(25)
Income tax	(9)	(19)	(22)	50	58	(87)	(164)	47
Dividends	(7)	(71)	(20)	90	64	(176)	(225)	22
Payment affiliated companies	-	-	8	-	(100)	1	68	(99)
Other Sources / Uses	(105)	5	(50)	(2,325)	(108)	(118)	(83)	(42)
Decrease (Increase) in Net Debt	(70)	(135)	(127)	48	45	(221)	(320)	31

TABLE 10 | STATEMENT OF FINANCIAL POSITION & FINANCIAL RATIOS (U.S. \$ Millions)

	4Q17	3Q17	4Q16	(%) 4Q17 vs.	
				3Q17	4Q16
Assets					
Cash and cash equivalents	484	447	142	8	241
Trade accounts receivable	544	507	542	7	0
Inventories	829	726	719	14	15
Other current assets	280	296	254	(5)	11
Total current assets	2,138	1,975	1,656	8	29
Investment in associates and others	33	33	28	1	18
Property, plant and equipment, net	2,105	2,117	1,970	(1)	7
Goodwill and intangible assets, net	206	211	575	(2)	(64)
Other non-current assets	270	227	200	19	35
Total assets	4,752	4,563	4,428	4	7
Liabilities & stockholders' equity					
Debt	375	380	135	(1)	178
Suppliers	874	741	636	18	37
Other current liabilities	170	186	168	(9)	1
Total current liabilities	1,420	1,307	939	9	51
Debt (include debt issuance cost)	1,366	1,254	1,043	9	31
Employees' benefits	54	61	59	(12)	(9)
Other long term liabilities	308	312	367	(1)	(16)
Total liabilities	3,147	2,935	2,409	7	31
Total stockholders' equity	1,604	1,628	2,019	(1)	(21)
Total liabilities & stockholders' equity	4,752	4,563	4,428	4	7
Net Debt	1,262	1,192	1,042	6	21
Net Debt/EBITDA*	3.3	3.2	1.6		
Interest Coverage*	4.8	5.4	10.5		

* Times: last 12 months

Polyester

TABLE 11 | REVENUES

	4Q17	3Q17	4Q16	(%) 4Q17 vs.		YTD17	YTD16	Ch. %
				3Q17	4Q16			
Total Revenues								
Ps. Millions	17,668	16,836	16,862	5	5	70,477	64,241	10
U.S. \$ Millions	933	945	851	(1)	10	3,724	3,444	8
Domestic Revenues								
Ps. Millions	3,679	4,108	4,473	(10)	(18)	17,446	17,092	2
U.S. \$ Millions	194	230	226	(16)	(14)	921	917	-
Foreign Revenues								
Ps. Millions	13,989	12,727	12,389	10	13	53,031	47,149	12
U.S. \$ Millions	739	714	625	3	18	2,804	2,528	11
Foreign / Total (%)	79	76	73			75	73	

TABLE 12 | OPERATING INCOME AND EBITDA

	4Q17	3Q17	4Q16	(%) 4Q17 vs.		YTD17	YTD16	Ch. %
				3Q17	4Q16			
Operating Income								
Ps. Millions	1,022	(9,208)	1,078	111	(5)	(6,815)	4,487	(252)
U.S. \$ Millions	54	(517)	54	110	(0)	(396)	241	(264)
EBITDA								
Ps. Millions	1,467	(899)	1,640	263	(11)	2,970	6,514	(54)
U.S. \$ Millions	77	(51)	82	253	(6)	147	349	(58)

TABLE 13 | COMPARABLE EBITDA

	4Q17	3Q17	4Q16	(%) 4Q17 vs.		YTD17	YTD16	Ch. %
				3Q17	4Q16			
EBITDA								
Ps. Millions	1,467	(899)	1,640	263	(11)	2,970	6,514	(54)
U.S. \$ Millions	77	(51)	82	253	(6)	147	349	(58)
Adjustments*								
Ps. Millions	(215)	1,864	(327)	(112)	34	1,489	(370)	503
U.S. \$ Millions	(11)	105	(16)	(111)	30	87	(18)	574
Comparable EBITDA								
Ps. Millions	1,252	965	1,313	30	(5)	4,458	6,145	(27)
U.S. \$ Millions	66	54	66	22	(0)	234	331	(29)

*Adjustments: Inventory and non-operating, one-time (gains) losses

Plastics & Chemicals

TABLE 14 | REVENUES

	4Q17	3Q17	4Q16	(%) 4Q17 vs.		YTD17	YTD16	Ch. %
				3Q17	4Q16			
Total Revenues								
P.s. Millions	7,342	6,538	6,566	12	12	28,522	25,951	10
U.S. \$ Millions	388	367	332	6	17	1,506	1,394	8
Domestic Revenues								
P.s. Millions	4,487	3,952	4,018	14	12	17,511	16,533	6
U.S. \$ Millions	237	222	203	7	17	925	890	4
Foreign Revenues								
P.s. Millions	2,855	2,587	2,548	10	12	11,011	9,418	17
U.S. \$ Millions	151	145	129	4	17	581	505	15
Foreign / Total (%)	39	40	39			39	36	

TABLE 15 | OPERATING INCOME AND EBITDA

	4Q17	3Q17	4Q16	(%) 4Q17 vs.		YTD17	YTD16	Ch. %
				3Q17	4Q16			
Operating Income								
P.s. Millions	1,071	832	898	29	19	3,966	5,413	(27)
U.S. \$ Millions	57	47	45	22	25	208	293	(29)
EBITDA								
P.s. Millions	1,203	959	1,039	25	16	4,519	5,948	(24)
U.S. \$ Millions	64	54	52	18	21	237	322	(26)

TABLE 16 | COMPARABLE EBITDA

	4Q17	3Q17	4Q16	(%) 4Q17 vs.		YTD17	YTD16	Ch. %
				3Q17	4Q16			
EBITDA								
P.s. Millions	1,203	959	1,039	25	16	4,519	5,948	(24)
U.S. \$ Millions	64	54	52	18	21	237	322	(26)
Adjustments*								
P.s. Millions	(94)	(2)	-	(5,794)	(100)	(167)	(253)	34
U.S. \$ Millions	(5)	-	-	(100)	(100)	(8)	(14)	41
Comparable EBITDA								
P.s. Millions	1,108	958	1,039	16	7	4,352	5,695	(24)
U.S. \$ Millions	59	54	52	9	12	229	308	(26)

*Adjustments: Inventory and non-operating, one-time (gains) losses

Appendix B – Financial Statements

ALPEK, S.A.B. DE C.V. and Subsidiaries

STATEMENT OF FINANCIAL POSITION

Information in Millions of Mexican Pesos

	Dec 17	Sep 17	Dec 16	(% Dec 17 vs.)	
				Sep 17	Dec 16
ASSETS					
CURRENT ASSETS:					
Cash and cash equivalents	8,795	7,427	2,935	18	200
Trade accounts receivable	10,739	9,222	11,191	16	(4)
Other accounts and notes receivable	4,152	3,938	3,626	5	15
Inventories	16,364	13,204	14,853	24	10
Other current assets	2,142	2,145	1,616	(0)	33
Total current assets	42,192	35,936	34,221	17	23
Investment in associates and others	650	594	575	9	13
Property, plant and equipment, net	41,535	38,518	40,699	8	2
Goodwill and intangible assets, net	4,065	3,845	11,875	6	(66)
Other non-current assets	5,336	4,138	4,130	29	29
Total assets	93,778	83,031	91,500	13	2
LIABILITIES AND STOCKHOLDER'S EQUITY					
CURRENT LIABILITIES:					
Debt	7,408	6,910	2,787	7	166
Suppliers	17,255	13,493	13,151	28	31
Other current liabilities	3,356	3,385	3,469	(1)	(3)
Total current liabilities	28,019	23,788	19,407	18	44
NON-CURRENT LIABILITIES:					
Debt (include debt issuance cost)	26,958	22,818	21,551	18	25
Deferred income taxes	4,403	4,136	5,883	6	(25)
Other liabilities	1,673	1,549	1,710	8	(2)
Employees' benefits	1,061	1,118	1,227	(5)	(14)
Total liabilities	62,114	53,409	49,778	16	25
STOCKHOLDERS' EQUITY:					
Controlling interest:					
Capital stock	6,048	6,048	6,048	-	-
Share premium	9,071	9,071	9,071	-	-
Contributed capital	15,119	15,119	15,119	-	-
Earned surplus	11,797	10,153	21,954	16	(46)
Total controlling interest	26,916	25,272	37,073	7	(27)
Non-controlling interest	4,748	4,350	4,649	9	2
Total stockholders' equity	31,664	29,622	41,722	7	(24)
Total liabilities and stockholders' equity	93,778	83,031	91,500	13	2

ALPEK, S.A.B. DE C.V. and Subsidiaries

STATEMENT OF INCOME

Information in Millions of Mexican Pesos

	4Q17	3Q17	4Q16	4Q17 vs.(%)		YTD17	YTD16	YTD17 vs. (%)
				3Q17	4Q16			YTD16
Revenues	25,010	23,374	23,428	7	7	98,998	90,192	10
Domestic	8,166	8,061	8,491	1	(4)	34,957	33,625	4
Export	16,844	15,313	14,937	10	13	64,041	56,567	13
Cost of sales	(21,941)	(21,133)	(20,615)	(4)	(6)	(88,598)	(76,943)	(15)
Gross profit	3,069	2,241	2,813	37	9	10,400	13,249	(22)
Operating expenses and others	(985)	(10,618)	(869)	91	(13)	(13,254)	(3,386)	(291)
Operating income	2,084	(8,377)	1,944	125	7	(2,854)	9,863	(129)
Financial cost, net	(1,296)	(2,312)	(719)	44	(80)	(3,410)	(2,509)	(36)
Share of losses of associates	-	1	2	(78)	(89)	(4)	(3)	(24)
Profit (loss) before income tax	788	(10,688)	1,227	107	(36)	(6,268)	7,351	(185)
Income tax	(1,173)	3,668	(582)	(132)	(102)	1,713	(2,358)	173
Consolidated net income (loss)	(385)	(7,020)	645	95	(160)	(4,555)	4,993	(191)
Profit (loss) attributable to Controlling interest	(577)	(7,130)	544	92	(206)	(5,487)	3,625	(251)
Profit attributable to Non-controlling interest	192	110	101	75	90	932	1,368	(32)